Download

Critical Appraisal






Advertisement
/ 36 []
Download Presentation
Comments
thi
From:
|  
(1192) |   (0) |   (0)
Views: 54 | Added:
Rate Presentation: 0 0
Description:
Critical Appraisal. DR Joshna Rajbaran. CARDIAC TROPONIN and OUTCOME in ACUTE HEART FAILURE. NEJM 358;20 MAY 15,2008. THE AIM:. To describe the association between elevated cardiac troponin levels and adverse events in hospitalized patients with ACUTE DECOMPENSATED HEART FAILURE. WHY??.
Critical Appraisal

An Image/Link below is provided (as is) to

Download Policy: Content on the Website is provided to you AS IS for your information and personal use only and may not be sold or licensed nor shared on other sites. SlideServe reserves the right to change this policy at anytime. While downloading, If for some reason you are not able to download a presentation, the publisher may have deleted the file from their server.











- - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - E N D - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -




Slide 1

Critical Appraisal

DR Joshna Rajbaran

Slide 2

CARDIAC TROPONIN and OUTCOME in ACUTE HEART FAILURE

NEJM 358;20 MAY 15,2008

Slide 3

THE AIM:

  • To describe the association between elevated cardiac troponin levels and adverse events in hospitalized patients with ACUTE DECOMPENSATED HEART FAILURE

Slide 4

WHY??

  • Because an objective risk-stratification process for the evaluation of acute decompensated heart failure is lacking.

Slide 5

  • The value of measuring serum cardiac troponin when a patient presents with acute decompensated heart failure remains uncertain.

Slide 6

NB: Troponins

Trop T & Trop I are regulatory proteins with a very high specificity for cardiac injury . They are released early ( 2-4 hrs) & can persist for up to 7 days.

Troponin testing is primarily used as a tool in diagnosing myocardial infarctions.

Elevated levels suggest myocardial or some form of cardiac damage.

Insignificant if used in the absence of S&S of cardiac disease!!

Slide 7

THE KEY DIFFERENCES

  • LARGE STUDY

  • SHORT TERM OUTCOMES

  • IN HOSPITALIZED PATIENTS WITH ACUTE DECOMPENSATED HEART FAILURE.

Slide 8

METHOD

  • Registry data:

    • ADHERE( Acute Decompensated Heart Failure National Registry)

    • Observational registry

    • 274 hospitals

    • TIME FRAME :October 2001 January 2004

Slide 9

  • Inclusion criteria:

    Hospitalization & documentation of the measurement of trop I or trop T at “INITIAL” evaluation

Slide 10

  • Exclusion criteria:

    serum creatinine level>2.0mg/dl

    or 176.8umol/l

  • Ischemic heart failure defined as cause if :

    hx coronary artery disease OR

    hx myocardial infarction

    Not as exclusion criteria!!!

Slide 11

METHOD

  • Troponin measurement:

  • Trop T & trop I were interchangeable levels considered positive, with cut-off based on expert consensus!!

  • Trop T≥0.1µg/l & Trop I ≥1.0µg/l

Slide 12

Method

  • Statistical analysis:

  • Primary out-come all causes

  • Secondary out-come differences in medical mx / procedures / length of stay between +ve & -ve cohorts

  • All outcomes were specified before the data were examined

Slide 13

  • Statistical analysis ( cont)

  • Associations between therapy & mortality

  • Controls used in this regard

  • Mortality was adjusted for relevant prognostic factors

Slide 14

  • Logistic regression adjusted for:

    age / blood urea nitrogen / SBP /

    DBP / serum creatinine / serum sodium / HR /dyspnea at rest

  • 1.2% records excluded due to missing values

Slide 15

  • SAS software

  • Study designed by all authors

  • ADHERE statisticians

Slide 16

METHOD

  • Source

  • Time period

  • Inclusion criteria

  • Exclusion criteria

  • IHD/Race / Gender

  • troponin measurements justified

  • Statistical analysis explained

  • Tools and teams stated

Slide 17

RESULTS

  • Troponin levels & characterists of the patients

Slide 18

105,388 84,872 ( 80.5% )

Hospitalized Trop tested

Cr < 2mg/dl

67,924

Positive Negative

4240 (6,2%) 63,684

Slide 19

  • There were small but significant differences between the two cohorts!!!

Slide 20

  • Troponin- positive patients on admission:

  • Lower SBP

  • Lower EF

  • Less likely AF

  • Summary of characteristics given +ve vs –ve Trop

  • No comparison made for the two proteins as only 2% had both tested!!

Slide 21

REVISION OF TERMINOLOGY

Odds ratio :provides a more useful way of presenting diagnostic data & can be applied to individual patients in a way that specificity & sensitivity cannot . It is a number btw 0 to infinity IF > 1 indicates that the information increases the likelihood of the suspected diagnoses. IF <1 it decreases the likelihood of the suspected diagnoses!!

Slide 22

SPECIFICITY: the proportion of patients WITHOUT the disease who are correctly identified by the test.

SENSITIVITY: the proportion of patients WITH the disease who are correctly identified by the test.

Slide 23

RESULTS

  • In-hospital mortality

  • Trop Positive (8.0%) > Trop Negative (2.7%) patients.......... (P<0.001)

  • Actuarial analysis

  • Trop as a continuous variable

  • Adjusted odds ratio for death (P<0.001)

Slide 24

  • IHF was not a useful discriminator of Troponin status, nor was it predictive of mortality.

  • IHF Trop +ve 53% Trop –ve 52%

  • Trop +ve mortality 8,4% IHF

    7,4% non-IHF

  • Trop –ve mortality 2,8% IHF

    2,6% non-IHF

Slide 25

RESULTS

  • Treatment , Troponin status & Mortality

  • Diuretics

  • +ve more likely to receive: nitroglycerine , inotropes & vasodilators

  • Resource utilization and mortality

  • No interaction between treatment & Troponin status with respect to mortality

Slide 26

RESULTS

  • Sample size large but justified

  • Basic data adequately described

  • Variables taken into account

  • Missing data accounted for

  • Numbers add up

  • High risk cohort established

  • Statistical significance assessed

Slide 27

Main findings and their value:

Prognostic value / cost

Early assessment of risk/ triage & management

Add to existing risk-stratification data for predicting the short term risk of death among patients with acute decompensated heart failure... Blood urea>15.4mmol/l

SBP < 115mm Hg

Cr >243.1µmol/l

More aggressive therapeutic approach justified

Slide 28

  • Value of findings from Trop negative cohort

    Identifying low risk patients/ planning Rx

  • Other studies the impact of early risk stratification has been supported

    BASEL TRIAL

    EFFECT STUDY

    SMALLER STUDIES-98 CONSECUTIVE PTS

    -159 PTS

    -RITZ-4 STUDY

Slide 29

  • Studies correlating Troponin with physiological variables

  • Impact on guidelines :

    National-ACS Trop & brain natriuretic peptide or N- terminal pro-brain peptide.

    Current for Heart Failure Trop NOT mentioned & brain nitriuretic peptide only if dx uncertain!!!

Slide 30

  • Suggested guideline!!!

  • Measurement of Troponin levels in patients who present with heart failure provides independent prognostic information regarding in hospital death & other clinical outcomes & can be useful for risk stratification of such patients!!!!

Slide 31

LIMITATIONS

  • Retrospective analysis

  • ADHERE large data set : investigator discretion , diagnosis not objectively ascertained , cause of death not consistently recorded

  • Troponin tests

  • Introduction of variability/ bias

  • Measurement only at admission

  • Interaction with other biomarkers

  • Under represented adverse outcomes

Slide 32

Critical appraisal

INFORMATIVE STUDY

AIM/METHOD/FINDINGS

SIGNIFICANCE

STRENGTHS & LIMITATIONS WITH SUGGESTIONS OFFERED

I FOUND NO REASON TO QUESTION THE STATISTICAL APPROACH

SUGGESTIONS FOR FUTURE STUDIES

OTHER RELEVANT STUDIES DOCUMENTED

Slide 33

With relevance to SA

  • South African statistics :10 473 mortalities per annum d/t Heart Failure vs. US 55,704

  • Further evaluation of other biomarkers vs Trop T required

  • Cost factors need to be examined

  • Ischaemic heart disease is the commonest cause for acute heart failure in America.

Slide 34

  • HOWEVER, in Sub- Saharan Africa the causes in Africans are largely ( > 90%) NON-ISCHAEMIC viz.:

    HPT / cardiomyopathy / Rheumatic heart disease / chronic lung disease / pericardial disease

  • Coronary artery disease and it’s complications remain uncommon in Africa but the situation is changing!!

Slide 35

  • I found the journal article rather transparent in it’s limitations

  • However, there was one limitation that seemed to stand out:

    that some patients with both heart failure and ACS may have been included!!!!

  • I think that with urbanization ,varying risk profiles amongst race groups , risk prone behaviour & diet, that the findings are worthy of consideration in our setting.

Slide 36

  • Finally , EARLY RISK STRATIFICATION may help identify patients who are likely to receive the greatest benefit from intensive therapy.....that in itself highlights it’s relevance to emergency medicine!!!!


Copyright © 2014 SlideServe. All rights reserved | Powered By DigitalOfficePro